Elevated levels of soluble ST2 but not galectin-3 are associated with increased risk of mortality in hemodialysis patients.

ABSTRACT:

Background

The soluble forms of suppression of tumorigenicity-2 (ST2) and galectin-3 have been proposed as novel biomarkers for cardiac fibrosis and heart failure, as well as predictors of cardiovascular events and mortality. However, there are limited data on the association between soluble ST2 and galectin-3 and clinical outcomes in patients with kidney failure on replacement therapy. To determine this, we examined the associations between soluble ST2 and galectin-3 and all-cause mortality and cardiovascular events in patients on hemodialysis.

Methods

This study included maintenance hemodialysis patients (over 18 years old) who consented to preserve their serum in the Biobank at our institution between March 2014 and March 2015. We used Cox proportional hazards regression

SUBMITTER: Kim AJ 

PROVIDER: S-EPMC8041640 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature